ArticleChinese medical journal pulmonary and critical care medicine2025
Temporal trends in the burden of tracheal, bronchial, and lung cancer in China and globally: A comprehensive analysis from 1990 to 2021.
Article in Chinese medical journal pulmonary and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Efficacy and toxicity of maintenance therapy with PD-1/PD-L1 inhibitors plus pemetrexed vs . immunotherapy alone for stage III/IV non-squamous non-small cell lung cancer: A real-world study.Chinese medical journal · 2026Article
- Publication Characteristics and Reporting Quality of GBD-Derived Burden of Disease Studies: A Cross-Sectional Analysis of Lung Cancer.Journal of evidence-based medicine · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tracheal, bronchial, and lung (TBL) cancer remains a leading cause of cancer-related deaths globally, with its burden influenced by aging populations, smoking, air pollution, and advances in treatment. China, as one of the most affected countries, faces significant challenges due to rapid industrialization and an aging population. This study aimed to systematically assess the temporal trends and disease burden of tracheal, bronchial, and lung cancer in China from 1990 to 2021, in comparison with global patterns, to provide evidence for targeted prevention and public health policymaking. Methods: Using data from the Global Burden of Disease (GBD) database (1990-2021), this study analyzed trends in the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of TBL cancer in China and globally. Joinpoint regression analysis was applied to identify significant changes in trends over time, and the average annual percentage change (AAPC) was calculated to quantify the overall temporal trends. Statistical significance was evaluated using Permutation tests, with results reported as 95 % confidence intervals (95 % CI). Results: In 2021, China accounted for 41.0 % (934,704 of 2,280,688) of global incident cases, 38.8 % (1,262,275 of 3,253,729) of global prevalent cases, 40.4 % (814,364 of 2,016,547) of global deaths, and 40.7 % (18,920,203 of 46,536,272) of global DALYs. The AAPC for China's age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized DALYs rate (ASDR) were 0.9 % (95 % CI: 0.8 % to 1.1 %, Conclusion: China bears a significant share of the global burden of TBL cancer. Over the last two decades, the growth rate of China's ASIR has slowed, while its ASMR and ASDR have declined, potentially attributable to advancements in targeted therapies and immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.